The Lancet Publishes Results from Gentium’s Phase III Defibrotide Trial for the Prevention of VOD in Pediatric Patients

Gentium announced that results from a Phase III randomized controlled trial which evaluated Defibrotide for use in preventing hepatic veno-occlusive disease (VOD) in paediatric patients undergoing haemopoietic stem-cell transplantation were published in the medical journal, The Lancet.
MarketWatch